Bernard Arulanandam to Administration, Intranasal
This is a "connection" page, showing publications Bernard Arulanandam has written about Administration, Intranasal.
Connection Strength
1.474
-
Cong Y, Jupelli M, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine. 2007 May 10; 25(19):3773-80.
Score: 0.300
-
Wali S, Gupta R, Veselenak RL, Li Y, Yu JJ, Murthy AK, Cap AP, Guentzel MN, Chambers JP, Zhong G, Rank RG, Pyles RB, Arulanandam BP. Use of a Guinea pig-specific transcriptome array for evaluation of protective immunity against genital chlamydial infection following intranasal vaccination in Guinea pigs. PLoS One. 2014; 9(12):e114261.
Score: 0.129
-
Murthy AK, Li W, Guentzel MN, Zhong G, Arulanandam BP. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge. Vaccine. 2011 Mar 21; 29(14):2519-22.
Score: 0.099
-
Yu JJ, Goluguri T, Guentzel MN, Chambers JP, Murthy AK, Klose KE, Forsthuber TG, Arulanandam BP. Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice. Clin Vaccine Immunol. 2010 Feb; 17(2):215-22.
Score: 0.091
-
Ketavarapu JM, Rodriguez AR, Yu JJ, Cong Y, Murthy AK, Forsthuber TG, Guentzel MN, Klose KE, Berton MT, Arulanandam BP. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9313-8.
Score: 0.082
-
Jupelli M, Guentzel MN, Meier PA, Zhong G, Murthy AK, Arulanandam BP. Endogenous IFN-gamma production is induced and required for protective immunity against pulmonary chlamydial infection in neonatal mice. J Immunol. 2008 Mar 15; 180(6):4148-55.
Score: 0.081
-
Li W, Murthy AK, Guentzel MN, Seshu J, Forsthuber TG, Zhong G, Arulanandam BP. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol. 2008 Mar 01; 180(5):3375-82.
Score: 0.080
-
Li W, Guentzel MN, Seshu J, Zhong G, Murthy AK, Arulanandam BP. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin Vaccine Immunol. 2007 Dec; 14(12):1537-44.
Score: 0.078
-
Murthy AK, Chambers JP, Meier PA, Zhong G, Arulanandam BP. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun. 2007 Feb; 75(2):666-76.
Score: 0.074
-
Murphey C, Murthy AK, Meier PA, Neal Guentzel M, Zhong G, Arulanandam BP. The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell Immunol. 2006 Aug; 242(2):110-7.
Score: 0.074
-
Murthy AK, Cong Y, Murphey C, Guentzel MN, Forsthuber TG, Zhong G, Arulanandam BP. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun. 2006 Dec; 74(12):6722-9.
Score: 0.073
-
Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun. 2006 Apr; 74(4):2063-71.
Score: 0.070
-
Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother. 2004 Dec; 48(12):4513-9.
Score: 0.064
-
Arulanandam BP, Raeder RH, Nedrud JG, Bucher DJ, Le J, Metzger DW. IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. J Immunol. 2001 Jan 01; 166(1):226-31.
Score: 0.049
-
Arulanandam BP, O'Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis. 1999 Oct; 180(4):940-9.
Score: 0.045
-
Arulanandam BP, Metzger DW. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine. 1999 Jan 21; 17(3):252-60.
Score: 0.043
-
Manam S, Chaganty BK, Evani SJ, Zafiratos MT, Ramasubramanian AK, Arulanandam BP, Murthy AK. Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice. PLoS One. 2013; 8(5):e64917.
Score: 0.029
-
Huber VC, Arulanandam BP, Arnaboldi PM, Elmore MK, Sheehan CE, Kallakury BV, Metzger DW. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol. 2003 Jun; 3(6):801-9.
Score: 0.014